Performance-enhancing Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

Performance-enhancing Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2018 - 2026

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description

Performance-enhancing drugs are substances intended to improve performance in athletic activities. Muscle development and increase in oxygen-carrying capacity of the blood are a few of the important impacts instigated by the utilization of performance-enhancing drugs. As per the Health Research Funding, in 2015, approximately 1,084,000 people in North America were found to include performance-enhancing drugs in their daily routine for some reason. Along with such a pattern of the utilization of performance-enhancing drugs, rising adoption is driving the performance-enhancing drugs market currently. Approximately 57% of the steroid consumers mentioned that they would keep on using steroids regardless of whether it shortens their lifespan. In addition, rising utilization of performance-enhancing drugs, also called anabolic steroids, for the treatment of disease conditions is projected to fuel the performance-enhancing drugs market in the near future. These conditions include weakness associated with anemia and certain types of breast malignancy.

The performance-enhancing drugs market is anticipated to expand at the maximum pace in developed countries with high per capita income, where these drugs are also employed for the treatment of breast cancer. The utilization of these medications leads to different adverse reactions. A few of the most common adverse reactions among men are decreased sperm generation and acne. In women, the most commonly found adverse reactions are masculinization and cardiac arrest. Additionally, as indicated by the Health Research Funding, the level of positive tests for anabolic medications doping in the world was around 50.6% in 2014. Such instances of doping forced the legal authorities to take steps and form strict rules regarding the sale and consumption of performance-enhancing drugs. This factor is estimated to restrict the performance-enhancing drugs market in the near future.

The global performance-enhancing drugs market can be segmented based on type of drug product, dosage form, and end-user. Based on type of drug product, the performance-enhancing drugs market can be segmented into nootropic, ergogenic aids, and others. The nootropic segment can be sub-segmented into ampakines, racetams, choline & acetylcholine intermediates, and others. The ergogenic aids segment can be sub-divided into dehydroepiandrosterone (DHEA), anabolic steroids, human growth hormone (HGH), and others. Based on dosage form, the global performance-enhancing drugs market can be classified into tablets, injections, patches, pills, and others. Based on end-user, the performance-enhancing drugs market can be divided into body builders, athletic persons, military professionals, students, and others.

Geographically, the global performance-enhancing drugs market has been segregated into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the global performance-enhancing drugs market followed by Europe. The U.S. and Canada hold a major share of the market in the region, as these are developed countries with high per capita income. Growth of the market in Europe is attributable to increased research and development activities and easy adoption of performance-enhancing drugs in the region. On the other hand, the market in Asia Pacific is expected to expand rapidly during the forecast period, owing to rising awareness about fitness, presence of continuously developing economies, and immense growth opportunities in the region. The market in Middle East & Africa is expected to witness sluggish growth during the forecast period, due to poor economy of the Africa sub-region.

The global performance-enhancing drugs market is dominated by key players such as Balkan Pharmaceuticals, AstraZeneca, BrainAlert, LLC, Taj Pharmaceuticals Limited, Novo Nordisk A/S, Eli Lilly and Company, Douglas Laboratories, and Bayer AG.

The report offers a comprehensive evaluation of the performance-enhancing drugs market. It does so via in-depth qualitative insights, historical data, and verifiable projections about performance-enhancing drugs market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the performance-enhancing drugs market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients